Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
170 hedge funds and large institutions have $3.23B invested in Blueprint Medicines in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 39 reducing their positions, and 12 closing their positions.
267% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 12
236% more call options, than puts
Call options by funds: $18.9M | Put options by funds: $5.63M
85% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 39
28% more capital invested
Capital invested by funds: $2.53B → $3.23B (+$703M)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
23% more funds holding
Funds holding: 138 → 170 (+32)
6.93% more ownership
Funds ownership: 92.75% → 99.69% (+6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$97.3M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$54.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$50.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$53.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$52M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$21.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$16.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.4M |
BPMC Hedge Fund Activity: Q4 2017 in Review
170 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2017, worth a combined $3.23B — up 28% from $2.53B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BPMC positions and 12 closed out — a net gain of 32 holders — while 72 added to existing stakes and 39 trimmed.
The largest buyer was Vanguard Group, adding an estimated $97.3M. The largest seller was PFM Health Sciences, cutting an estimated $53.6M.
- 170 institutional investors held Blueprint Medicines (BPMC) as of Q4 2017, up from 138 in Q3 2017.
- Funds reported $3.23B of Blueprint Medicines stock for Q4 2017, up 28% quarter-over-quarter.
- 44 funds opened new Blueprint Medicines positions in Q4 2017 and 12 closed out, a net change of +32 holders.
- The largest Blueprint Medicines buyer in Q4 2017 was Vanguard Group, an estimated $97.3M added.
- The largest Blueprint Medicines seller in Q4 2017 was PFM Health Sciences, an estimated $53.6M sold.
Based on aggregated 13F filings for Q4 2017.